Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy of Pixantrone with rituximab, ifosfamide and etoposide
as measured by the overall metabolic response rate after 2 cycles of treatment or at
permanent treatment discontinuation.